Physician profile
Gregory T Bjorklund
NPI 1932127669
$46,745.19
in general payments reported to CMS, 2019-2025
25 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $2,746 · 2023: $12K · 2024: $2,905 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $6,371 · Travel and Lodging: $1,612 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,831.25 |
| Food and Beverage | $6,370.80 |
| Travel and Lodging | $1,612.48 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18,448.94 | 2021-2025 | |
| Emd Serono, INC. | $10,252.39 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $8,234.82 | 2021-2025 | Vumerity, Tysabri, Spinraza |
| E.R. Squibb & Sons, L.L.C. | $3,689.57 | 2021-2024 | Zeposia |
| Celgene Corporation | $2,149.02 | 2021-2024 | Zeposia |
| Tg Therapeutics, INC. | $1,742.96 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,151.24 | 2021-2025 | Kesimpta |
| Ani Pharmaceuticals, INC. | $192.51 | 2023 | Purified Cortrophin Gel |
| Genentech USA, INC. | $184.04 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Ucb, INC. | $143.44 | 2024-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $127.97 | 2021-2025 | Ultomiris |
| Acorda Therapeutics, INC | $100.79 | 2021-2023 | Inbrija |
| Argenx US, INC. | $64.61 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Greenwich Biosciences, INC. | $48.97 | 2021 | |
| Horizon Therapeutics Plc | $40.05 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $26.70 | 2023 | Amvuttra |
| Eisai INC. | $23.68 | 2024 | |
| Amylyx Pharmaceuticals, INC. | $19.60 | 2024 | Relyvrio |
| Invivyd INC | $17.83 | 2025 | Pemgarda |
| Averitas Pharma INC. | $16.13 | 2025 | Qutenza |
| Springworks Therapeutics, INC. | $15.55 | 2025 | Gomekli |
| Sanofi-Aventis U.S. LLC | $14.78 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.53 | 2025 | Acthar |
| Pfizer INC. | $12.78 | 2023 | |
| Abbvie INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Bjorklund listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.